Literature DB >> 22045759

FDA advisory decision highlights some problems inherent in pragmatic trials.

Mike Mitka.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22045759     DOI： 10.1001/jama.2011.1570

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  3 in total

1.  Rivaroxaban in atrial fibrillation.

Authors:  Mariano A Giorgi; Lucas San Miguel
Journal:  Vasc Health Risk Manag       Date:  2012-08-30

2.  A comparison of meta-analytic methods for synthesizing evidence from explanatory and pragmatic trials.

Authors:  Tolulope T Sajobi; Guowei Li; Oluwagbohunmi Awosoga; Meng Wang; Bijoy K Menon; Michael D Hill; Lehana Thabane
Journal:  Syst Rev       Date:  2018-01-25

3.  Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose.

Authors:  Kirsty Loudon; Merrick Zwarenstein; Frank Sullivan; Peter Donnan; Shaun Treweek
Journal:  Trials       Date:  2013-04-27       Impact factor: 2.279
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.